

Special Issue

Molecular Research of Triple-Negative Breast Cancer

Message from the Guest Editors

Breast cancer is classified on the basis of histological and molecular variability; a subgroup equally heterogeneous is triple-negative breast cancer (TNBC), which shows lost expression of PR, ER and HER2/NEU receptors and a general molecular expression that confers it a particularly metastatic and invasive nature, drug resistance and poor prognosis. Therefore, several subtypes that actually have no specific molecular targets characterize TNBC and, consequently, a feature that makes it difficult to set a valid therapeutic strategy and so, to date, conventional chemotherapy is the only choice. The Special Issue aims to collect recent results in this context, as:

- Genetic, epigenetic, transcriptional profiles;
- Description of proteomic features and/or biochemical pathways;
- Identification of cancer stem cells and their cross-talk with microenvironment; metabolic reprogramming;
- Effect induced in vitro/in vivo of any (or combination of) drugs;
- Triple-negative breast cancer immunity and metabolic reprogramming;
- Any evidence useful to suggest and define novel molecular target to challenge the aggressive character of TNBC.

Guest Editors

Dr. Anna De Blasio

Laboratory of Biochemistry, Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, 90127 Palermo, Italy

Dr. Daniela Carlisi

Section of Biochemistry, Department of Biomedicine, Neuroscience and Advanced Diagnostic, University of Palermo, 90127 Palermo, Italy

Deadline for manuscript submissions

closed (31 May 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/138402

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).